Vascular Biogenics Ltd. (NASDAQ:VBLT) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

Several other brokerages have also weighed in on VBLT. Zacks Investment Research raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 16th. HC Wainwright set a $11.00 target price on shares of Vascular Biogenics and gave the stock a “buy” rating in a research note on Tuesday, August 15th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Vascular Biogenics has an average rating of “Hold” and a consensus price target of $12.90.

Vascular Biogenics (VBLT) remained flat at $5.05 during midday trading on Friday. 38,317 shares of the stock were exchanged. The stock’s market capitalization is $136.40 million. The stock’s 50-day moving average price is $4.66 and its 200-day moving average price is $5.18. Vascular Biogenics has a 52 week low of $3.90 and a 52 week high of $6.70.

Vascular Biogenics (NASDAQ:VBLT) last announced its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. On average, analysts expect that Vascular Biogenics will post ($0.74) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Vascular Biogenics Ltd. (VBLT) Downgraded to Sell at ValuEngine” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at

A hedge fund recently bought a new stake in Vascular Biogenics stock. KCG Holdings Inc. acquired a new stake in Vascular Biogenics Ltd. (NASDAQ:VBLT) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 45,106 shares of the biopharmaceutical company’s stock, valued at approximately $248,000. KCG Holdings Inc. owned 0.17% of Vascular Biogenics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 11.28% of the company’s stock.

About Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with's FREE daily email newsletter.